Alterome to Present Cancer Trial Data in November
San Diego firm will showcase new clinical and preclinical findings on its KRAS inhibitor at an upcoming symposium.
Updated on Oct. 27, 2026 in Cancer
Live Poll
Should regulatory requirements for cancer drug clinical trials be relaxed to accelerate patient access?
Alterome Therapeutics is scheduled to unveil Phase 1/1b clinical trial results for its KRAS-selective inhibitor ALTA3263 on November 20, 2026. The San Diego-based company will also present preclinical data regarding monotherapy and combination treatments at the 38th EORTC-NCI-AACR Symposium.
Why it matters
The study evaluates a novel approach to treating advanced solid tumors, including colorectal cancer and pancreatic ductal adenocarcinoma, by targeting specific oncogenic mutations. This research aims to address critical needs in oncology through an orally available therapeutic agent.
The clinical presentation is filed under abstract number 7LBA, while preclinical findings are detailed in abstract 202. The trial utilizes a Phase 1 dose-escalation design to study the inhibitor in patients with advanced solid tumors.
The players
Alterome Therapeutics
A San Diego-based biopharmaceutical company focused on the development of precision oncology treatments.
David S. Hong
The lead researcher scheduled to present the clinical data findings at the 38th EORTC-NCI-AACR Symposium.
The details
ALTA3263 functions by inhibiting KRAS mutations in both ON and OFF states, offering a unique mechanism for cancer treatment. Preclinical data further demonstrates that the inhibitor maintains activity when used in combination with cetuximab.
Timeline
Preclinical data will be presented on November 19, 2026.
Clinical trial data will be presented on November 20, 2026.
The Big Picture
The presentation of ALTA3263 at the 38th EORTC-NCI-AACR Symposium marks a significant step in current oncology research. The company is utilizing this major scientific symposium to broadcast its latest progress in KRAS inhibition technology to the global medical community.
This research trial may eventually expand treatment options for patients diagnosed with advanced solid tumors, including pancreatic and colorectal cancers. Participants in clinical trials may gain access to novel therapies that target mutations not addressed by standard treatments.
The takeaway
The upcoming symposium will provide critical insights into whether ALTA3263 can effectively target KRAS mutations in clinical settings. Future developments in this research could represent a shift in how clinicians manage advanced solid tumor diagnoses.
What happens next
Preclinical data presentation on November 19, 2026, and the clinical data presentation on November 20, 2026.
Further reading
Learn more about ongoing developments in Cancer treatments and research.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should regulatory requirements for cancer drug clinical trials be relaxed to accelerate patient access?
